DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 2 minutes ago

KVUE·Kenvue Inc.

$.
-. (-.%)
After Hours
High
$19.10
Open
$18.91
Market Cap
36.52B
52W High
$22.87
Low
$18.78
P. Close
$18.99
P/E
22.51
52W Low
$14.02
Fwd P/E
59.19
DailyIQ Est.
$19.76
Technical Score (1D)
50
NEUTRAL
News Sentiment
68
BULLISH
Barclays has just lifted its price target for Kenvue to $19 from $18, while keeping its equal‑weight rating unchanged. The upgrade signals that the bank now sees stronger upside potential in the company’s growth prospects and product pipeline. If Kenvue delivers on its guidance, the higher target could support a rally in the next 1–10 trading days. Traders should focus on the upcoming earnings release, where management’s outlook and any new regulatory approvals will be disclosed. A positive earnings report or a new product launch could validate the higher target and lift sentiment. Conversely, weaker-than‑expected results or delays in approvals could undermine the upgrade and weigh on the stock. Watch for any changes in the rating or target from other analysts, as that could further influence market perception. Keep an eye on the regulatory landscape, particularly any FDA decisions that could affect Kenvue’s product pipeline. Finally, monitor broader market conditions that could impact the pharmaceutical sector, such as interest‑rate moves or macro‑economic data releases.
Earnings Summary
KVUE, a global consumer health company headquartered in Summit, New Jersey, markets a broad portfolio of well‑known over‑the‑counter and personal care brands such as Tylenol, Neutrogena, Johnson’s baby care, and Band‑Aid. Operating within the consumer defensive sector and the household & personal products industry, KVUE serves consumers worldwide with essential health and beauty solutions. In the most recent reporting cycle, KVUE posted EPS of $0.27 in Q4 2025 and $0.32 in Q1 2026, both surpassing analyst expectations of $0.2256 and $0.30627 respectively, while revenue climbed from $3.78 billion to $3.91 billion, a 3.4 % year‑over‑year gain. Compared to the prior two quarters—Q2 2025 EPS $0.29 and revenue $3.84 billion, Q3 2025 EPS $0.28 and revenue $3.76 billion—KVUE’s earnings trajectory shows a modest dip in Q4 followed by a stronger rebound in Q1 2026, and a revenue trend that has been largely upward with only a brief 2 % decline between Q2 and Q3. Historically, the company has consistently beaten EPS estimates in every quarter since 2024, with revenue growth maintained even when EPS missed in a single period, underscoring a resilient operating model. Recent analyst commentary highlights UBS and HSBC raising price targets to $20, reflecting confidence in KVUE’s product pipeline, while a federal appeals court has allowed autism‑related claims linked to Tylenol to proceed, potentially increasing legal expenses; the pending $48.7 billion acquisition bid by Kimberly‑Clark adds upside potential if regulatory approval is secured. Investors should watch for guidance updates in the next earnings release, any commentary on litigation costs or settlement progress, and developments in the acquisition process, as these factors will likely shape the company’s valuation trajectory in the coming quarters.

EPS

EstBeatMiss
$0.21$0.24$0.27$0.30$0.33Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.32 - -
Q1'26$0.31$0.32+4.5%
Q4'25$0.23$0.27+19.7%
Q3'25$0.26$0.28+5.7%
Q2'25$0.28$0.29+2.2%
Q1'25$0.23$0.24+5.4%

Revenue

EstBeatMiss
$3.7B$3.8B$3.9B$4.0B$4.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.0B - -
Q1'26$3.9B$3.9B-0.3%
Q4'25$3.8B$3.8B+0.7%
Q3'25 - $3.8B -
Q2'25 - $3.8B -
Q1'25 - $3.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

KVUE Stock Snapshot

KVUE is currently trading at $19.09, giving Kenvue Inc. a market cap of 36.52B and a P/E ratio of 22.5. Today's range spans $18.78–$19.10, with shares opening at $18.91 and moving up $0.10 (0.5%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 68/100.

Over the past year KVUE has traded between $14.02 and $22.87 - the current price is +36.2% off the 52-week low and -16.5% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $19.75 (range $18.00–$23.00), implying upside of +3.5%.

Neutral technical setups in large-cap Consumer Defensive names are inherently unstable - they resolve. Right now, KVUE (50/100, HOLD, price $19.09, in the middle of its 52-week range) is waiting for that resolution. Sentiment: bullish at 68/100. The current P/E ratio stands at 22.5. With 36.52B in market cap, the 52-week range of $14.02–$22.87 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

The 52-week range of $14.02–$22.87 for KVUE provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $19.09 (in the middle of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 50/100 and bullish news backdrop (68/100) don't break the tie yet, but they narrow the probability distribution toward the upside.